Treating Multiple Myeloma in 2017: New Agents, New Challenges

Jointly provided by

Support for this activity has been provided through educational grants from Celgene and Takeda Oncology.

Scroll to the Bottom of this Information to Begin this Course

Release date: February 14, 2017

Valid through: February 14, 2018

Specialty: Hematology/Oncology, Oncology

Topic: Multiple Myeloma

Media: Internet

Estimated Time to Complete Activity: 60 minutes

Target Audience

This activity has been designed to meet the educational needs of hematologist-oncologists, medical oncologists, oncology nurses, and other health care providers involved in the care of patients with multiple myeloma (MM).

Program Overview

A steadily growing list of drugs for MM has provided more options for patient management in the frontline and salvage settings—but it has also complicated the process of selecting a regimen that balances immediate efficacy with long-term consequences and quality of life. Adding to the challenge is the fact that two newly approved agents represent an entirely new class of drug for MM management—the monoclonal antibodies—which bring with them their own set of practice challenges in optimizing their use. This activity has been developed to help physicians who treat MM patients keep pace with the exciting but rapidly growing and frequently updated body of clinical data regarding the newest MM agents and their role in practical patient care.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Factor the indicated uses, mechanisms of action, and safety of newly available therapies when determining treatment plans for patients with MM
  • Outline a treatment plan for patients with MM to achieve the most durable response while balancing the risk for toxicities

Credit Available

  • Physicians — maximum of 1.0 AMA PRA Category 1 Credit

All other health care professionals completing this course will be issued a statement of participation.

Faculty

Thomas G. Martin, III, MD

Professor of Clinical Medicine
Associate Director Myeloma Program
University of California, San Francisco (UCSF) Medical Center
Clinical Research Director Hematologic Malignancies
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, California

Click here for Dr. Martin's Bio 

Suzanne Lentzsch, MD, PhD

Professor of Medicine at CUMC
College of Physicians and Surgeons
Columbia University
Director, Multiple Myeloma and Amyloidosis Service
New York Presbyterian Hospital/Columbia University Medical Center
New York, New York

Click here for Dr. Lentzsch's Bio 

Physician Continuing Medical Education

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Penn State College of Medicine, RedMedEd, and the Multiple Myeloma Research Foundation. Penn State College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

Penn State College of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosures of Conflicts of Interest

In accordance with the ACCME Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of everyone in a position to control content of an educational activity. A relevant financial relationship is a relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears below:

Thomas G. Martin, III, MD
  • Research Grant: Amgen, Sanofi Oncology
Suzanne Lentzsch, MD, PhD
  • Research Grant: Celgene
  • Speakers Bureau: Bristol-Myers Squibb, Clinical Care Options, Novartis, Takeda
Penn State College of Medicine
  • Faculty and staff involved in the development and review of this activity have disclosed no relevant financial relationships.

Multiple Myeloma Research Foundation

Mary DeRome, Director of Medical Communications and Education
  • Consultant/Advisor: Amgen
Anne Quinn Young, MPH, Senior Vice President, Marketing & Communications
  • No relevant financial relationships

RedMedEd

Denise C. LaTemple, PhD, Director of Scientific Services
  • No relevant financial relationships
Jonathan S. Simmons, ELS, Senior Managing Editor
  • No relevant financial relationships
Karen Smith, Creative Director
  • No relevant financial relationships
Karen Tenaglia, Project Manager
  • No relevant financial relationships

Instructions for Participation and Credit

There are no fees to participate in the activity. Participants must review all activity information, including the learning objectives, disclosure statements, and content. To receive CME credit for participation, participants must complete the posttest (achieving a passing grade of 80% or greater) and program evaluation. Certificates can be printed immediately.

For questions regarding CME credit, contact Penn State Continuing Education at (717) 531-6483 or ContinuingEd@hmc.psu.edu. Please reference activity code G6043-17-V.

For technical questions related to this activity, please contact RedMedEd at (610) 251-6841 or education@redmeded.com.

Hardware and Software Requirements

This site is best viewed with an HTML5 compatible browser, this list includes the current versions of Microsoft Internet Explorer, Mozilla Firefox, Google Chrome, and Apple's Safari. You can visit the independent (3rd party) site www.whatismybrowser.com to determine if you have the latest version of your browser. Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. That software may be: Adobe Flash, Apple Quicktime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, and Real Networks Real One Player. Where such software is required it will be indicated.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Penn State College of Medicine, RedMedEd, the Multiple Myeloma Research Foundation, Celgene, and Takeda Oncology do not recommend the use of any agent outside the labeled indications.

Disclaimer

The information presented at this activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician regarding diagnosis and treatment of a specific patient’s medical condition.

The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Penn State College of Medicine, RedMedEd, the Multiple Myeloma Research Foundation, Celgene, or Takeda Oncology. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.